At a glance
ClinicalIndex Comparison Record- ✓Histologically confirmed large B-cell, CD20-positive non-Hodgkin's lymphoma
- ✓No prior treatment for lymphoma
- ✓Clinical stage II, III, or IV disease
- ✓Age older than 70 years
- ✕Central nervous system involvement with lymphoma
- ✕Coexistent active malignancies treated within five years
- ✕Active infection precluding combination chemotherapy
- ✕HIV infection
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase II Trial of Brief Duration Combination Chemotherapy and Rituximab With Prophylactic Pegfilgrastim, Followed by Maintenance Rituximab, in Elderly/Poor Performance Status Patients With Large B-Cell Non-Hodgkin's Lymphoma
In Brief
A Phase 2 clinical trial evaluating Cyclophosphamide, Mitoxantrone, and 3 other interventions for Non-Hodgkins Lymphoma. Completed, enrolled 51 participants across 2 sites.
Detailed Summary
The purposes of this trial are to decrease toxicity and improve treatment effectiveness elderly patients. With a short course of chemotherapy with cyclophosphamide, mitoxantrone, vincristine, and prednisone with concurrent administration of rituximab it is likely to be as effective as longer programs, and will certainly be better tolerated by this patient group. The addition of maintenance therapy may result in substantial prolongation of remission duration.
Study Details
Timeline
Interventions
Cyclophosphamide
Mitoxantrone
Vincristine
Prednisone
Rituximab